Lung Cancer Genomic Testing Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, and Others), By Sample Type (Tissue Biopsy and Liquid Biopsy), By Panel Type (Multi-Gene Panel and Single-Gene Panel), By End-User (Research Organization, Hospitals & Clinics, Diagnostic Laboratories, Others), By Region and Competition, 2020-2030F
The Global Lung Cancer Genomic Testing Medicine Market will grow from USD 1.90 Billion in 2024 to USD 2.59 Billion by 2030 at a 5.30% CAGR. Lung cancer genomic testing medicine encompasses the analysis of tumor deoxyribonucleic acid to identify specific genetic mutations or alterations, enabling the selection of personalized therapeutic strategies for patients. The market's growth is primarily driven by the rising global incidence of lung cancer, continuous advancements in genomic sequencing technologies such as Next-Generation Sequencing, and an increasing imperative for precision medicine approaches in oncology.
Key Market Drivers
The market for global lung cancer genomic testing medicine is significantly influenced by the increasing worldwide incidence of lung cancer. This escalating disease burden creates an urgent demand for advanced diagnostic tools to facilitate precise patient stratification and guide targeted therapeutic interventions. Lung cancer consistently ranks as a leading cause of cancer-related mortality globally, necessitating innovation in diagnostic capabilities.
Key Market Challenges
The substantial cost associated with advanced genomic testing represents a significant impediment to the growth of the Global Lung Cancer Genomic Testing Medicine Market. High test expenses directly limit patient access, particularly in healthcare systems facing budgetary constraints or where comprehensive reimbursement policies are not fully established. This financial barrier can deter clinicians from ordering these essential tests and prevent patients from undergoing molecular profiling, thereby restricting the overall adoption rate of precision medicine strategies in lung cancer.
Key Market Trends
Artificial intelligence and machine learning are significantly enhancing lung cancer genomic interpretation, improving speed and accuracy for complex data analysis. These technologies enable precise identification of actionable mutations crucial for targeted therapies. For instance, the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer showcased an AI tool, DeepGEM, for gene mutation prediction from histopathology slides, with data from 3,658 patients analyzed.
Key Market Players
In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Genomic Testing Medicine Market.
Available Customizations:
Global Lung Cancer Genomic Testing Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
The market for global lung cancer genomic testing medicine is significantly influenced by the increasing worldwide incidence of lung cancer. This escalating disease burden creates an urgent demand for advanced diagnostic tools to facilitate precise patient stratification and guide targeted therapeutic interventions. Lung cancer consistently ranks as a leading cause of cancer-related mortality globally, necessitating innovation in diagnostic capabilities.
Key Market Challenges
The substantial cost associated with advanced genomic testing represents a significant impediment to the growth of the Global Lung Cancer Genomic Testing Medicine Market. High test expenses directly limit patient access, particularly in healthcare systems facing budgetary constraints or where comprehensive reimbursement policies are not fully established. This financial barrier can deter clinicians from ordering these essential tests and prevent patients from undergoing molecular profiling, thereby restricting the overall adoption rate of precision medicine strategies in lung cancer.
Key Market Trends
Artificial intelligence and machine learning are significantly enhancing lung cancer genomic interpretation, improving speed and accuracy for complex data analysis. These technologies enable precise identification of actionable mutations crucial for targeted therapies. For instance, the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer showcased an AI tool, DeepGEM, for gene mutation prediction from histopathology slides, with data from 3,658 patients analyzed.
Key Market Players
- QIAGEN NV
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings
- CENTOGENE N.V.
- BGI Genomics Co. Ltd.
- CeGaT GmbH
- Illumina Inc.
- F. Hoffmann-La Roche Ltd
In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Lung Cancer Genomic Testing Medicine Market, By Technology:
- Polymerase Chain Reaction
- Next-Generation Sequencing
- Fluorescence In-Situ Hybridization
- Others
- Lung Cancer Genomic Testing Medicine Market, By Sample Type:
- Tissue Biopsy
- Liquid Biopsy
- Lung Cancer Genomic Testing Medicine Market, By Panel Type:
- Multi-Gene Panel
- Single-Gene Panel
- Lung Cancer Genomic Testing Medicine Market, By End-User:
- Research Organization
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
- Lung Cancer Genomic Testing Medicine Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Genomic Testing Medicine Market.
Available Customizations:
Global Lung Cancer Genomic Testing Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, Others)
5.2.2. By Sample Type (Tissue Biopsy, Liquid Biopsy)
5.2.3. By Panel Type (Multi-Gene Panel, Single-Gene Panel)
5.2.4. By End-User (Research Organization, Hospitals & Clinics, Diagnostic Laboratories, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. NORTH AMERICA LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Sample Type
6.2.3. By Panel Type
6.2.4. By End-User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Lung Cancer Genomic Testing Medicine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Sample Type
6.3.1.2.3. By Panel Type
6.3.1.2.4. By End-User
6.3.2. Canada Lung Cancer Genomic Testing Medicine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Sample Type
6.3.2.2.3. By Panel Type
6.3.2.2.4. By End-User
6.3.3. Mexico Lung Cancer Genomic Testing Medicine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Sample Type
6.3.3.2.3. By Panel Type
6.3.3.2.4. By End-User
7. EUROPE LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Sample Type
7.2.3. By Panel Type
7.2.4. By End-User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Lung Cancer Genomic Testing Medicine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Sample Type
7.3.1.2.3. By Panel Type
7.3.1.2.4. By End-User
7.3.2. France Lung Cancer Genomic Testing Medicine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Sample Type
7.3.2.2.3. By Panel Type
7.3.2.2.4. By End-User
7.3.3. United Kingdom Lung Cancer Genomic Testing Medicine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Sample Type
7.3.3.2.3. By Panel Type
7.3.3.2.4. By End-User
7.3.4. Italy Lung Cancer Genomic Testing Medicine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Sample Type
7.3.4.2.3. By Panel Type
7.3.4.2.4. By End-User
7.3.5. Spain Lung Cancer Genomic Testing Medicine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Sample Type
7.3.5.2.3. By Panel Type
7.3.5.2.4. By End-User
8. ASIA PACIFIC LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Sample Type
8.2.3. By Panel Type
8.2.4. By End-User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Lung Cancer Genomic Testing Medicine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Sample Type
8.3.1.2.3. By Panel Type
8.3.1.2.4. By End-User
8.3.2. India Lung Cancer Genomic Testing Medicine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Sample Type
8.3.2.2.3. By Panel Type
8.3.2.2.4. By End-User
8.3.3. Japan Lung Cancer Genomic Testing Medicine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Sample Type
8.3.3.2.3. By Panel Type
8.3.3.2.4. By End-User
8.3.4. South Korea Lung Cancer Genomic Testing Medicine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Sample Type
8.3.4.2.3. By Panel Type
8.3.4.2.4. By End-User
8.3.5. Australia Lung Cancer Genomic Testing Medicine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Sample Type
8.3.5.2.3. By Panel Type
8.3.5.2.4. By End-User
9. MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Sample Type
9.2.3. By Panel Type
9.2.4. By End-User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Lung Cancer Genomic Testing Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Sample Type
9.3.1.2.3. By Panel Type
9.3.1.2.4. By End-User
9.3.2. UAE Lung Cancer Genomic Testing Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Sample Type
9.3.2.2.3. By Panel Type
9.3.2.2.4. By End-User
9.3.3. South Africa Lung Cancer Genomic Testing Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Sample Type
9.3.3.2.3. By Panel Type
9.3.3.2.4. By End-User
10. SOUTH AMERICA LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Sample Type
10.2.3. By Panel Type
10.2.4. By End-User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Lung Cancer Genomic Testing Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Sample Type
10.3.1.2.3. By Panel Type
10.3.1.2.4. By End-User
10.3.2. Colombia Lung Cancer Genomic Testing Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Sample Type
10.3.2.2.3. By Panel Type
10.3.2.2.4. By End-User
10.3.3. Argentina Lung Cancer Genomic Testing Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Sample Type
10.3.3.2.3. By Panel Type
10.3.3.2.4. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL LUNG CANCER GENOMIC TESTING MEDICINE MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. QIAGEN NV
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Agilent Technologies Inc.
15.3. Thermo Fisher Scientific Inc.
15.4. Quest Diagnostics Incorporated
15.5. Laboratory Corporation of America Holdings
15.6. CENTOGENE N.V.
15.7. BGI Genomics Co. Ltd.
15.8. CeGaT GmbH
15.9. Illumina Inc.
15.10. F. Hoffmann-La Roche Ltd
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, Others)
5.2.2. By Sample Type (Tissue Biopsy, Liquid Biopsy)
5.2.3. By Panel Type (Multi-Gene Panel, Single-Gene Panel)
5.2.4. By End-User (Research Organization, Hospitals & Clinics, Diagnostic Laboratories, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. NORTH AMERICA LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Sample Type
6.2.3. By Panel Type
6.2.4. By End-User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Lung Cancer Genomic Testing Medicine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Sample Type
6.3.1.2.3. By Panel Type
6.3.1.2.4. By End-User
6.3.2. Canada Lung Cancer Genomic Testing Medicine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Sample Type
6.3.2.2.3. By Panel Type
6.3.2.2.4. By End-User
6.3.3. Mexico Lung Cancer Genomic Testing Medicine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Sample Type
6.3.3.2.3. By Panel Type
6.3.3.2.4. By End-User
7. EUROPE LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Sample Type
7.2.3. By Panel Type
7.2.4. By End-User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Lung Cancer Genomic Testing Medicine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Sample Type
7.3.1.2.3. By Panel Type
7.3.1.2.4. By End-User
7.3.2. France Lung Cancer Genomic Testing Medicine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Sample Type
7.3.2.2.3. By Panel Type
7.3.2.2.4. By End-User
7.3.3. United Kingdom Lung Cancer Genomic Testing Medicine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Sample Type
7.3.3.2.3. By Panel Type
7.3.3.2.4. By End-User
7.3.4. Italy Lung Cancer Genomic Testing Medicine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Sample Type
7.3.4.2.3. By Panel Type
7.3.4.2.4. By End-User
7.3.5. Spain Lung Cancer Genomic Testing Medicine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Sample Type
7.3.5.2.3. By Panel Type
7.3.5.2.4. By End-User
8. ASIA PACIFIC LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Sample Type
8.2.3. By Panel Type
8.2.4. By End-User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Lung Cancer Genomic Testing Medicine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Sample Type
8.3.1.2.3. By Panel Type
8.3.1.2.4. By End-User
8.3.2. India Lung Cancer Genomic Testing Medicine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Sample Type
8.3.2.2.3. By Panel Type
8.3.2.2.4. By End-User
8.3.3. Japan Lung Cancer Genomic Testing Medicine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Sample Type
8.3.3.2.3. By Panel Type
8.3.3.2.4. By End-User
8.3.4. South Korea Lung Cancer Genomic Testing Medicine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Sample Type
8.3.4.2.3. By Panel Type
8.3.4.2.4. By End-User
8.3.5. Australia Lung Cancer Genomic Testing Medicine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Sample Type
8.3.5.2.3. By Panel Type
8.3.5.2.4. By End-User
9. MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Sample Type
9.2.3. By Panel Type
9.2.4. By End-User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Lung Cancer Genomic Testing Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Sample Type
9.3.1.2.3. By Panel Type
9.3.1.2.4. By End-User
9.3.2. UAE Lung Cancer Genomic Testing Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Sample Type
9.3.2.2.3. By Panel Type
9.3.2.2.4. By End-User
9.3.3. South Africa Lung Cancer Genomic Testing Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Sample Type
9.3.3.2.3. By Panel Type
9.3.3.2.4. By End-User
10. SOUTH AMERICA LUNG CANCER GENOMIC TESTING MEDICINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Sample Type
10.2.3. By Panel Type
10.2.4. By End-User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Lung Cancer Genomic Testing Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Sample Type
10.3.1.2.3. By Panel Type
10.3.1.2.4. By End-User
10.3.2. Colombia Lung Cancer Genomic Testing Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Sample Type
10.3.2.2.3. By Panel Type
10.3.2.2.4. By End-User
10.3.3. Argentina Lung Cancer Genomic Testing Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Sample Type
10.3.3.2.3. By Panel Type
10.3.3.2.4. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL LUNG CANCER GENOMIC TESTING MEDICINE MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. QIAGEN NV
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Agilent Technologies Inc.
15.3. Thermo Fisher Scientific Inc.
15.4. Quest Diagnostics Incorporated
15.5. Laboratory Corporation of America Holdings
15.6. CENTOGENE N.V.
15.7. BGI Genomics Co. Ltd.
15.8. CeGaT GmbH
15.9. Illumina Inc.
15.10. F. Hoffmann-La Roche Ltd
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
